These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 4465958)
41. Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia. Yamada K; Kanba S; Ohnishi K; Ashikari I; Yagi G; Asai M Biol Psychiatry; 1997 May; 41(10):1062-4. PubMed ID: 9129786 [No Abstract] [Full Text] [Related]
42. Tardive dyskinesia and pseudo-parkinsonism. In a nursing home patient who itched. Ondo WG; Hurwitz BJ N C Med J; 1993 Nov; 54(11):605-7. PubMed ID: 8272117 [No Abstract] [Full Text] [Related]
43. [Current treatment of Parkinsonian syndrome]. Lechner H; Bertha G; Ott E Med Welt; 1980 Oct; 31(40):1444-6. PubMed ID: 7464500 [No Abstract] [Full Text] [Related]
44. Effect of amantadine on drug-induced parkisonism: relationship between plasma levels and effect. Pacifici GM; Nardini M; Ferrari P; Latini R; Fieschi C; Morselli PL Br J Clin Pharmacol; 1976 Oct; 3(5):883-9. PubMed ID: 788761 [TBL] [Abstract][Full Text] [Related]
45. Amantadine in the neuroleptic malignant syndrome. Gangadhar BN; Desai NG; Channabasavanna SM J Clin Psychiatry; 1984 Dec; 45(12):526. PubMed ID: 6501243 [No Abstract] [Full Text] [Related]
46. Troxonium tosylate in the treatment of drug-induced extrapyramidal manifestations. Koh CV; Ananth JV; Ban TA; Lehmann HE Int Z Klin Pharmakol Ther Toxikol; 1971 Apr; 4(3):289-91. PubMed ID: 4931413 [No Abstract] [Full Text] [Related]
47. [A case of corticobasal degeneration of which movemental disturbances were improved by administration of amantadine]. Yasuoka T; Ikeda M; Maki N; Hokoishi K; Komori K; Tanabe H No To Shinkei; 2001 Aug; 53(8):781-5. PubMed ID: 11577423 [TBL] [Abstract][Full Text] [Related]
48. [Clinical trial of the therapeutic effect of Amantadine-HCL in Parkinson's Disease]. Hacohen H; Gurtner B Schweiz Med Wochenschr; 1972 Apr; 102(16):583-6. PubMed ID: 5019377 [No Abstract] [Full Text] [Related]
50. Mental health research at a state hospital. An attempt at a balanced program. Rappaport M Ment Hyg; 1968 Jan; 52(1):110-23. PubMed ID: 4229896 [No Abstract] [Full Text] [Related]
51. [Crises in the course of Parkinson's disease]. Danielczyk W Wien Med Wochenschr; 1980 Feb; 130(4):149-51. PubMed ID: 7376682 [No Abstract] [Full Text] [Related]
52. [Study of the delayed-action form of a synthetic antiparkinsonian drug: Akineton]. Kammerer T; Schweitzer-Bucher E; Jamet P; Royer M Ann Med Psychol (Paris); 1972 May; 1(5):688-96. PubMed ID: 5081112 [No Abstract] [Full Text] [Related]
56. Pharmacokinetics and clinical effects of amantadine in drug-induced extrapyramidal symptoms. Greenblatt DJ; DiMascio A; Harmatz JS; Bernardo DL; Marder JE J Clin Pharmacol; 1977; 17(11-12):704-8. PubMed ID: 336651 [TBL] [Abstract][Full Text] [Related]
57. Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms. Fayen M; Goldman MB; Moulthrop MA; Luchins DJ Am J Psychiatry; 1988 Apr; 145(4):483-6. PubMed ID: 2894780 [TBL] [Abstract][Full Text] [Related]
58. [Amantadine in malignant neuroleptic syndrome]. Rojtman M; Apter E; Lahav S; Tiano S Harefuah; 1981 Apr; 100(7):333. PubMed ID: 6115795 [No Abstract] [Full Text] [Related]
59. Assessment of drugs in schizophrenia. Asessment of drug-induced extrapyramidal reactions and of drugs given for their control. Mindham RH Br J Clin Pharmacol; 1976 Jun; 3(3 Suppl 2):395-400. PubMed ID: 9965 [TBL] [Abstract][Full Text] [Related]